Par Acquires Spectrum's Interest in Sumatriptan Injection

Par Pharmaceutical Companies, Inc. announced that it amended its agreement with Spectrum Pharmaceuticals, Inc. for $20 million in cash to increase its share of profits from the generic versions of GlaxoSmithKline's Imitrex Injection, which will be immediately accretive to 2008 earnings and provide a strong return on the Company's investment.
CNN Money